Intersect ENT Reports First Quarter 2021 Financial Results
— Increases 2021 Revenue Guidance to $117 Million to $121 Million — MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT),...
Day: May 10, 2021
Neutrisci Announces Successful Completion of Phase 1 R&D Development of a Cannabinol Product
VANCOUVER, BC / ACCESSWIRE / May 10, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V: NU, OTCQB: NRXCF,...
Study Investigates the Ability of Masimo O3® to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality
Researchers Found That O3 May Help Clinicians Rapidly Assess Circulatory Status in Patients Experiencing Septic Shock and Have Prognostic Value...